Morgan Stanley Has Lowered Expectations for Avalyn Pharma (NASDAQ:AVLN) Stock Price

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) had its price target decreased by investment analysts at Morgan Stanley from $57.00 to $53.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price target suggests a potential upside of 77.85% from the stock’s current price.

AVLN has been the subject of several other research reports. Raymond James Financial initiated coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday. Finally, Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalyn Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.20.

Read Our Latest Report on AVLN

Avalyn Pharma Stock Down 1.6%

Avalyn Pharma stock traded down $0.48 during mid-day trading on Monday, reaching $29.80. The company had a trading volume of 13,792 shares, compared to its average volume of 340,556. The company has a current ratio of 25.76, a quick ratio of 25.76 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.33 billion and a price-to-earnings ratio of -1.31. The stock’s 50 day simple moving average is $28.66. Avalyn Pharma has a 52 week low of $22.24 and a 52 week high of $40.17.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, analysts predict that Avalyn Pharma will post -3.83 earnings per share for the current fiscal year.

Insider Activity at Avalyn Pharma

In related news, insider Fmr Llc sold 175,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00. Following the completion of the transaction, the insider directly owned 2,109,535 shares in the company, valued at approximately $61,324,182.45. This represents a 7.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Investors Weigh In On Avalyn Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Montanova Capital LLC bought a new stake in Avalyn Pharma in the 2nd quarter valued at $82,402,000. Braidwell LP bought a new position in shares of Avalyn Pharma during the 2nd quarter worth about $26,382,000. State Street Corp bought a new position in shares of Avalyn Pharma during the 2nd quarter worth about $10,501,000. Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma during the 2nd quarter worth about $1,321,000. Finally, Profund Advisors LLC acquired a new stake in shares of Avalyn Pharma during the 3rd quarter valued at about $668,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.

Featured Articles

Analyst Recommendations for Avalyn Pharma (NASDAQ:AVLN)

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.